Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways

Objectives Age is the strongest risk factor of giant cell arteritis (GCA), implying a possible pathogenetic role of cellular senescence. To address this question, we applied an established senescence specific multimarker algorithm in temporal artery biopsies (TABs) of GCA patients. Methods 75(+) TABs from GCA patients, 22(−) TABs from polymyalgia rheumatica (PMR) patients and 10(−) TABs from non-GCA/non-PMR patients were retrospectively retrieved and analysed. Synovial tissue specimens from patients with inflammatory arthritis and aorta tissue were used as disease control samples. Senescent cells and their histological origin were identified with specific cellular markers; IL-6 and MMP-9 were investigated as components of the senescent associated secretory phenotype by triple costaining. GCA or PMR artery culture supernatants were applied to fibroblasts, HUVECs and monocytes with or without IL-6R blocking agent to explore the induction of IL-6-associated cellular senescence. Results Senescent cells were present in GCA arteries at higher proportion compared with PMR (9.50% vs 2.66%, respectively, p<0.0001) and were mainly originated from fibroblasts, macrophages and endothelial cells. IL-6 was expressed by senescent fibroblasts, and macrophages while MMP-9 by senescent fibroblasts only. IL-6(+) senescent cells were associated with the extension of vascular inflammation (transmural inflammation vs adventitia limited disease: 10.02% vs 4.37%, respectively, p<0.0001). GCA but not PMR artery culture supernatant could induce IL-6-associated senescence that was partially inhibited by IL-6R blockade. Conclusions Senescent cells with inflammatory phenotype are present in GCA arteries and are associated with the tissue inflammatory bulk, suggesting a potential implication in disease pathogenesis.

[1]  V. Gorgoulis,et al.  Escape from senescence: molecular basis and therapeutic ramifications , 2023, The Journal of pathology.

[2]  E. Brouwer,et al.  Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis , 2023, Arthritis & rheumatology.

[3]  M. Serrano,et al.  Hallmarks of aging: An expanding universe , 2022, Cell.

[4]  Soyoung Lee,et al.  COVID-19 and cellular senescence , 2022, Nature Reviews Immunology.

[5]  C. Dani,et al.  Senescent macrophages in the human adipose tissue as a source of inflammaging , 2022, GeroScience.

[6]  E. Vicente-Rabaneda,et al.  Advances in the Treatment of Giant Cell Arteritis , 2022, Journal of clinical medicine.

[7]  F. Buettner,et al.  Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. , 2022, Cancer cell.

[8]  B. Stripp,et al.  Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis , 2022, European Respiratory Journal.

[9]  Daniele Di Mauro,et al.  New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? , 2021, The Lancet. Rheumatology.

[10]  P. Subramanian,et al.  Targeted RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Temporal Arteries From Giant Cell Arteritis Cases Reveals Viral Signatures , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[11]  A. Lazaris,et al.  Neutrophil extracellular traps in giant cell arteritis biopsies: presentation, localization and co-expression with inflammatory cytokines. , 2021, Rheumatology.

[12]  J. Campisi,et al.  Algorithmic assessment of cellular senescence in experimental and clinical specimens , 2021, Nature Protocols.

[13]  J. Gil,et al.  Senescence and the SASP: many therapeutic avenues , 2020, Genes & development.

[14]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[15]  M. T. B. Geller,et al.  Molecular , 2019, Modern Pathology.

[16]  V. Gorgoulis,et al.  Senescence and senotherapeutics: a new field in cancer therapy , 2019, Pharmacology & therapeutics.

[17]  L. Tian,et al.  MMP (Matrix Metalloprotease)-9–Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis , 2018, Circulation research.

[18]  C. Kallenberg,et al.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? , 2018, Arthritis & rheumatology.

[19]  S. Melov,et al.  Unmasking Transcriptional Heterogeneity in Senescent Cells , 2017, Current Biology.

[20]  A. Rizzo,et al.  New insights into the pathogenesis of giant cell arteritis. , 2017, Autoimmunity reviews.

[21]  C. Wijmenga,et al.  A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. , 2017, American journal of human genetics.

[22]  Dimitris Kletsas,et al.  Robust, universal biomarker assay to detect senescent cells in biological specimens , 2016, Aging cell.

[23]  Sagar,et al.  DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas , 2016, Cell.

[24]  C. Conover,et al.  Senescent intimal foam cells are deleterious at all stages of atherosclerosis , 2016, Science.

[25]  E. Mavrogonatou,et al.  Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β , 2016, Aging.

[26]  Ansar Karimian,et al.  Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. , 2016, DNA repair.

[27]  A. Enjuanes,et al.  Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis , 2015, Annals of the rheumatic diseases.

[28]  L. Cimino,et al.  MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis , 2015, Annals of the rheumatic diseases.

[29]  P. Barnes,et al.  Dysfunction of Endothelial Progenitor Cells from Smokers and Chronic Obstructive Pulmonary Disease Patients Due to Increased DNA Damage and Senescence , 2013, Stem cells.

[30]  C. Weyand,et al.  Immune mechanisms in medium and large-vessel vasculitis , 2013, Nature Reviews Rheumatology.

[31]  C. Franceschi,et al.  MicroRNAs linking inflamm-aging, cellular senescence and cancer , 2013, Ageing Research Reviews.

[32]  Mahboob Rahman,et al.  Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis , 2013, Annals of the rheumatic diseases.

[33]  F. Hafner,et al.  NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica , 2013, Annals of the rheumatic diseases.

[34]  D. Abraham,et al.  Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis , 2012, Annals of the rheumatic diseases.

[35]  A. Iagnocco,et al.  2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. , 2012, Arthritis and rheumatism.

[36]  A. Iagnocco,et al.  2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative , 2012, Annals of the rheumatic diseases.

[37]  Y. J. Liao,et al.  Giant cell arteritis: immune and vascular aging as disease risk factors , 2011, Arthritis research & therapy.

[38]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[39]  R. Olshen,et al.  Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.

[40]  Javier Martín,et al.  Epidemiology of giant cell arteritis and polymyalgia rheumatica. , 2009, Arthritis and rheumatism.

[41]  J. Nolla,et al.  Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. , 2007, Seminars in arthritis and rheumatism.

[42]  J. Grau,et al.  Gelatinase expression and proteolytic activity in giant-cell arteritis , 2007, Annals of the rheumatic diseases.

[43]  C. Nordborg,et al.  Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis , 2005, Annals of the rheumatic diseases.

[44]  J. Stone,et al.  Metalloproteinase-2 and -9 in Giant Cell Arteritis: Involvement in Vascular Remodeling , 2005, Circulation.

[45]  D. Colomer,et al.  Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. , 2003, Rheumatology.

[46]  Dolors Colomer,et al.  Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis: Angiogenic Activity of Interleukin-6 as a Potential Protective Mechanism , 2003, Circulation.

[47]  A. Papavassiliou,et al.  p53 activates ICAM‐1 (CD54) expression in an NF‐κB‐independent manner , 2003 .

[48]  G. Hannon,et al.  Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Hunder,et al.  Tissue Cytokine Patterns in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis , 1994, Annals of Internal Medicine.

[50]  J. Goronzy,et al.  Functional profile of tissue-infiltrating and circulating CD68+ cells in giant cell arteritis. Evidence for two components of the disease. , 1994, The Journal of clinical investigation.

[51]  OUP accepted manuscript , 2021, Carcinogenesis.

[52]  B. Coll-Vinent,et al.  Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. , 2000, Arthritis and rheumatism.